CIPLA's weekly performance was disappointing, with a return of -1.86% and a Sharpe Ratio of -0.46, indicating poor risk-adjusted returns. The stock's volatility was high at 21.15%, making it a risky investment this week. Compared to its peers, CIPLA underperformed SUNPHARMA and DIVISLAB, but was in line with GRASIM's performance. Overall, investors should exercise caution due to the stock's high volatility and poor returns.

[Volatility: 21.15%]